Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
<"The advisory committee is advisory. Period. It is not a judge and jury. It is not the O.J. trial. It is not: "If the glove fits, you must acquit." It is the advice we are looking at, not the vote. We are more interested in the reasons why people are voting.">
so by implication, the FDA understands the motivations as to why members of the advisory committee voted the way they did and that is the determinative factor for the FDA's decision...
as a former DNDN shareholder this sure sounds like Pazdur is responding specifically to the ongoing Dendreon/Provenge/FDA saga rather than general FDA policy.
and his implicit admission that advisory committee member motivations play a key role in FDA decision-making seems rather self-incriminating considering the treatment was unanimously considered safe and a substantial majority of scientific professionals considered it efficacious, aside from the very conflicted Howard Scher et al.
i can only conclude that the real reason/motivation the FDA turned down Provenge can only be determined by following the money...imo, that provided the prime motivation for the FDA's denial/delay.
in some ways, Pazdur's statement above seems to support this, perhaps even intending to taunt Provenge supporters to try to make such a case, believing himself & his conflicted buddies above reproach.
pazdur is so full of it & himself, it is almost as disgusting as von eschenbach's lack of spinal chord...
thanks for a very informative & insightful explanation.
your moniker made me think of another cancer stock i followed several years back - ONCY - someone posted under the name "geneman" and from what i recall, he/you? was one of the few knowledgeable & informative posters who wasn't swept away by hype.
OT Countrywide CEO Mozillo selling $400M of his CFC insider holdings while the company itself was buying shares back on the market (to support the share price) just before the subprime implosion last summer is nothing short of obscene.
to believe his claims now that he didn't know what was going on & that the timing of his insider sales was simply fortuitous & coincidental shows the level of depravity of this guy, imo.
there is a lot of blame to go around, like rampant speculators buying property for nothing down & a quick flip, but ultimately, it is the CEOs of lenders that get paid millions annually to manage risk that have to bear the bulk of the responsibility.
Mozillo should be hung out to dry & spend some time in a different type of "big house".
there are a lot of potentially hidden "time bombs" ticking in surprising places resulting from this subprime mortgage mess.
some more on auction rate securities...
"While the vast majority of the auction rate securities have long-term maturities, they began being treated as short-term investments by many corporations several years ago due to the fact they're ordinarily very liquid and can be sold off at monthly auctions. Most audit firms in late 2004 began advising corporate clients to classify their auction rate securities as short-term, as opposed to cash or cash equivalents. More on this in a moment.
The incentive for corporations to invest in auction rate securities is obvious - with tons of cash on their balance sheets, many corporate treasurers began looking for ways to increase the return on that cash. That's actually a prudent strategy... as long as the market for auction rate securities is functioning. But the issue here (one that the SEC even investigated a few years ago) is that the market, although large in nominal dollar volume, is quite thin, controlled often by one dealer. Under ordinary circumstances, if there are too few bids the dealer will prop up the market by entering to place a final "clearing" bid. That practice of "propping up" the market is what the SEC probed a few years ago.
As BMY explained in the conference call, some of the short-term securities they invested in were unable to be sold at auction and the sponsoring brokers refused to make a market in the securities, or in this case refused to "prop it up," exactly what many feared would happen if liquidity issues developed.
BMY maintains there will be no impact on overall financial flexibility going forward, but the company, like many many others still has a sizable auction rate securities portfolio. Unable to liquidate these "short-term securities" as needed, remember this is supposed to be a cash management tool, the company could be forced to take additional impairment charges if credit market conditions continue to deteriorate. The alternative to the impairment charges? Suddenly owning long-term debt with maturities of 20-30 years. In other words, a bad trade just became an investment."
http://www.minyanville.com/articles/index.php?a=15733
iwfal, interesting that you have followed this company, though i think that has to be due only to its science, certainly not its management.
Another word of caution re: Thompson
the company issued a press release back in early 2001 headlining that they had filed for their first Phase II trial (in Canada for prostate cancer).
this trial was subsequently re-characterized by the company several years later as a "proof of concept", after ending it prematurely even tho they took a couple of years to partially enroll something like 6 or 12 patients!!!
When I personally spoke to Thompson about this he suggested it never was a Phase II trial and had never been represented as such, which I later learned was contrary to the contents of the earlier press release.
OT <I suppose the frenzied worldwide sell-off could mark a bottom>
Corporate Default Risk Soars to Record on Ambac Ratings Cut
The risk of European companies defaulting soared to a record on concern credit ratings cuts at bond insurers Ambac Financial Group Inc. and MBIA Inc. may trigger forced asset sales and worsen credit market turmoil.
Credit-default swaps on the Markit iTraxx Europe index of 125 companies with investment-grade ratings jumped 10.25 basis points to 82.5, according to JPMorgan Chase & Co., the highest since the index started in 2004.
Ambac was stripped of its top AAA grade by Fitch Ratings on Jan. 18 after the New York-based company abandoned plans to raise new equity. Moody's Investors Service and Standard & Poor's are reviewing Ambac and MBIA, throwing doubt on the ratings of the $2.4 trillion of debt guaranteed by bond insurers and threatening forced sales by investors that are restricted to holding the highest-grade bonds.
http://www.bloomberg.com/apps/news?pid=20601101&sid=ajTu_MsCCO5Q&refer=japan
Forced liquidation of the highest-grade corporate bonds by investors due to a ratings cut of undercapitalized bond insurers (whose shares are trading in single digits after trading as high as in the $90 range over the past 52 weeks) is going to increase supply (perhaps dramatically) of corporate bonds and drive down bond prices (in order to provide the increased yield necessary to compensate for the perceived increased risk).
It could send the corporate debt markets into even more turmoil after having already been stung by the subprime mess (not to mention concerns about commercial real estate, credit cards, and lower rated corporate debt etc.) I'm certainly no expert, but it isn't inconceivable to me that extensive problems in a market the size of $2.4 trillion could trigger a seizure/meltdown of the financial system...
perhaps a bottom will be found here though for a layman like me, it might only be visible & verifiable after the fact - this is uncharted territory & serious stuff imho.
regards
<The Bylaw Amendments were necessary due to rule changes promulgated by The American Stock Exchange that require AMEX-listed companies, including the Company, to ensure that their listed securities are eligible for participation in a direct registration system ("DRS") by January 1, 2008.
To comply with these rules, the Company must, among other things, be authorized to issue some or all of its listed securities in uncertificated form. The Bylaw Amendment amends and restates Sections 7.1, 7.3, 7.4 and 7.5 of Article VII of the Amended and Restated Bylaws. Prior to the Bylaw Amendments, the Bylaws required shares to be certificated and did not allow for the transfer of uncertificated shares.>
per my understanding, only shares in non-certificate form are eligible to be shorted (legally).
i'm not certain if this change will make it easier or harder for naked shorting (stock showing up on RegSHO list) to occur, tho my read is that it will make it easier...
<RPRX on the Reg SHO list is a big surprise>
If my understanding is correct (based on my experience with DNDN), I think it should be an outrage to current shareholders.
shorters (usually hedge funds) can't find enough shares to short, so they pay full commissions & interest to their brokerage buddies for selling shares on their behalf that don't legally exist (i.e. failed to deliver), which opens the door to manipulation and abuse by those with big enough pockets, perhaps on a massive scale - for an eg. just check out the volume on DNDN just before the AC panel & after its rec and the FDA's CR letter.
by creating artificial supply of stock, particularly for a company with an already very low 13M shares outstanding, they can artificially depress the price and stack the odds for the direction of the stock (i.e downward) in their favor.
all officially sanctioned by the exchanges, the brokerages and the SEC who imo are complicit by their inaction in helping hedge funds (the politicos largest campaign contributers) in screwing mainly retail shareholders.
thanks for the clarification wall.
I was just blowing off some steam re: Scher - even tho I'm no longer a DNDN shareholder, I think I probably would still be if it weren't for guys like Scher in & out of the FDA who imo sabotaged Provenge.
A lot of people will blame DNDN shareholder for being naive when it comes to the FDA process, and tho i'll accept some of that criticism, that only serves to remove the focus from where it primarily belongs imo & that is Scher, Pazdur & von Eschenbach's FDA.
thanks for letting me get that off my chest.
regards
OT I tried to send a pm but don't have those privileges so i am posting publicly to determine the specific reason why my post was deleted.
I don't see much in your reply that suggests that you found anything offensive in my post. I did express a strong opinion & thoughts about Scher which apparently aren't welcome here.
Censorship with no warning, no notification, no nothing...as an investor, i must say i am not impressed with that kind of "dilution" either.
<Scher is in by far the worst position, because he did not disclose his relationship with NOVC nor his relationship with Proquest. Then there is the potential that he was an oncologist source for the short hedge funds over the years regarding DNDN/Provenge.>
as it is, the stench from Scher not having recused himself from the panel due to his obvious conflicts re: Provenge is bad enough, but if they (congress, CTL, etc.) can dig up enough dirt on this douchebag to prove that he did use his influence to the detriment of Provenge & for the benefit of NOVC & his own pocketbook (perhaps via hedge fund consulting or otherwise) then I hope he fries here before he gets to hell.
then again, it would not surprise me that he felt/feels immune to any possible repercussions of any untoward involvement with delaying/defeating Provenge since he was & apparently still is highly regarded in the scientific community (as it relates to prostate cancer) & his imo reputation gives him sufficient cover for any questionable opinions he might have expressed on Provenge science - would the FDA now publicly admit they wouldn't have granted Scher a waiver if he had disclosed his other conflicts? I strongly doubt it, since that would add to the controversy over their Provenge decision and give more ammunition for those looking to broaden the scope of any investigation to include others (eg. Pazdur, etc.) - no way that FDA & Pazdur support that, imo.
and since the hedge funds are likely also current (and/or potential future) significant campaign contributors, I doubt Scher felt/feels he has much to worry about on that front either.
i suspect he was & still is a smug, self-righteous pompous, self-serving Ahole, like it appears a lot of those in positions of power seem to be these days.
<Nonetheless, the canary in the mine metaphor still applies because the CFO typically has less to gain—and more to lose—than other corporate executives by remaining with a biotech company whose prospects are sinking.>
so conversely, schiffman jumping affymetrix's ship and joining dndn meant affx was sinking and the previous two DNDN CFOs were wrong???
way, way too simplistic and imo, dangerous deductive thinking.
a cfo leaving a biotech could be a warning sign to shareholders as would be the case with any departure of a senior executive, but by no means is it necessarily suggestive or indicative of a problem.
imo, simonetti & burris's departure from dndn were for very different reasons, and neither had much to do with dndn's prospects (which looked pretty darn good after the panel vote)
and btw, burris's new employer's stock trbn has taken a 50% hair cut in the year she has been cfo there - which should be sufficient proof that a cfo's actions aren't always reliable business/stock indicators.
regards
At the suggestion of DewDiligence, I am reposting this here for any comments from those more acquainted with the science aspects
Amorfix Life Sciences discovers common link between ALS and Alzheimer's Disease
TORONTO, Nov. 27 /CNW/ - Amorfix Life Sciences (TSX: AMF - News), a company focused on treatments and diagnostics for brain-wasting diseases, today announced the discovery of misfolded superoxide dismutase 1 (SOD1) protein in the brains of people with Alzheimer's Disease. This breakthrough result suggests that SOD1 is a common link between the two brain-wasting diseases, Alzheimer's and ALS, also known as Lou Gehrig's Disease. SOD1 has a "Jekyll-and-Hyde" nature as it normally plays an important protective role in detoxifying free radicals in the body, but when misfolded can create lethal oxidative free radicals.
"Amorfix previously reported results from pilot studies showing our proprietary antibodies and vaccines targeting misfolded SOD1 showed life extension in a mouse model of ALS. Amorfix will now investigate the use of these same or similar agents to treat Alzheimer's disease," said Dr. Neil Cashman, Chief Scientific Officer of Amorfix. "Evidence of free radical toxicity has been observed in Alzheimer's disease for many years and the discovery of the presence of misfolded SOD1 strongly suggests this toxicity is associated with SOD1."
"The early success of our ALS therapeutic program targeting misfolded SOD1 together with the growing scientific evidence from external sources, gives us confidence to expand our product pipeline to include a treatment for Alzheimer's Disease," said Dr. George Adams, CEO of Amorfix Life Sciences. "While many companies are developing potential Alzheimer's disease treatments focused on the Abeta amyloid protein, Amorfix will use a novel approach based on Dr. Cashman's pioneering research on the importance of SOD1."
Amorfix's technology targets misfolded SOD1 through two approaches, a passive infusion of manufactured monoclonal antibodies and an active immunization approach designed to elicit the production of similar antibodies by the patient's own body. Amorfix's technology is based on the premise that the misfolding and aggregation of SOD1 is a principal agent in the death of neurons that occurs in brain-wasting diseases. Amorfix believes that if misfolded SOD1 can be specifically recognized and its toxic activity neutralized by antibodies, brain-wasting diseases could be effectively treated.
Amorfix's technology related to the role of SOD1 in ALS and Alzheimer's is covered by patent applications including one recently published entitled, "Methods and Compositions to treat and Detect Misfolded-SOD1 Mediated Diseases". The patent application relates to the methods and compositions for treating and detecting conditions, disease and disorders mediated by non-native SOD1.>
fwiw, market cap at today's closing price of $1.17 is just over $48M Cdn, with about $11M in working capital at the end of their Sep qtr.
Amorfix Life Sciences discovers common link between ALS and Alzheimer's Disease
TORONTO, Nov. 27 /CNW/ - Amorfix Life Sciences (TSX: AMF - News), a company focused on treatments and diagnostics for brain-wasting diseases, today announced the discovery of misfolded superoxide dismutase 1 (SOD1) protein in the brains of people with Alzheimer's Disease. This breakthrough result suggests that SOD1 is a common link between the two brain-wasting diseases, Alzheimer's and ALS, also known as Lou Gehrig's Disease. SOD1 has a "Jekyll-and-Hyde" nature as it normally plays an important protective role in detoxifying free radicals in the body, but when misfolded can create lethal oxidative free radicals.
"Amorfix previously reported results from pilot studies showing our proprietary antibodies and vaccines targeting misfolded SOD1 showed life extension in a mouse model of ALS. Amorfix will now investigate the use of these same or similar agents to treat Alzheimer's disease," said Dr. Neil Cashman, Chief Scientific Officer of Amorfix. "Evidence of free radical toxicity has been observed in Alzheimer's disease for many years and the discovery of the presence of misfolded SOD1 strongly suggests this toxicity is associated with SOD1."
"The early success of our ALS therapeutic program targeting misfolded SOD1 together with the growing scientific evidence from external sources, gives us confidence to expand our product pipeline to include a treatment for Alzheimer's Disease," said Dr. George Adams, CEO of Amorfix Life Sciences. "While many companies are developing potential Alzheimer's disease treatments focused on the Abeta amyloid protein, Amorfix will use a novel approach based on Dr. Cashman's pioneering research on the importance of SOD1."
Amorfix's technology targets misfolded SOD1 through two approaches, a passive infusion of manufactured monoclonal antibodies and an active immunization approach designed to elicit the production of similar antibodies by the patient's own body. Amorfix's technology is based on the premise that the misfolding and aggregation of SOD1 is a principal agent in the death of neurons that occurs in brain-wasting diseases. Amorfix believes that if misfolded SOD1 can be specifically recognized and its toxic activity neutralized by antibodies, brain-wasting diseases could be effectively treated.
Amorfix's technology related to the role of SOD1 in ALS and Alzheimer's is covered by patent applications including one recently published entitled, "Methods and Compositions to treat and Detect Misfolded-SOD1 Mediated Diseases". The patent application relates to the methods and compositions for treating and detecting conditions, disease and disorders mediated by non-native SOD1.>
fwiw, market cap at today's closing price of $1.17 is just over $48M Cdn, with about $11M in working capital at the end of their Sep qtr.
would welcome any comments from those less scientifically challenged than myself on the science aspects...
Technical Analysis Update - if there was any doubt whether the uptrend line dating all the way back to the May 2005 $1.50 low would hold up, today's emphatic close below $4 removed it.
From a technical standpoint, imo the next few trading days will be critical for JAV as to whether there will be a "quick recovery" in the stock, or whether there is some lingering bad news out there.
Assuming this sell-off has not been due to a leak of impending bad news, a quick bounce back from today's low and recovery to around $4.15 (representing the next resistance/former support level) is quite possible, if not likely to me - that would represent almost a 20% snap back from current levels.
in the absence of bad news being disclosed, i think an institution forced to liquidate its holdings represents a plausible explanation given the deteriorating market conditions. on the other hand, the volume for the past two weeks of the drop hasn't exactly been earth-shattering, though it has picked up the past few trading days as the price decline deepens. is it due to the need for more & faster liquidation of an institution or due to a leak spreading of impending bad news?
a partial answer imo will be provided with tomorrow's trading - the last full day of trading until next Monday - if the overall market stabilizes, i would expect JAV to recover fairly quickly to the $4.15 level if there is no bad news specific to JAV out there...if the JAV selling continues or picks up greater steam, that would imo point to the leaking of bad news as a more plausible explanation.
might be a great buying opportunity, but the technical breakdown over the past two days gives me pause to be cautious, especially considering that the broader markets & Amex biotech index were all up today while JAV sold off over 10% on increasing volume.
<Shorting a stock under $5 isn't permitted in the U.S.>
fyi, short interest in DNDN increased 60% from jan to mar to approximately 40% of the float while the stock was trading below $5 prior to its advisory committee meeting.
that was a heavily manipulated stock (later appeared on Reg SHO) and is just one example i am rather familiar with - there are are many other biotechs under $5 where short positions exist and have increased while under $5.
in fact, development stage biotechs are a popular short candidate for hedge funds exactly because most of them never manage to get a drug approved.
OT - <I think the majority of us would agree that both parties are equally guilty of all of the ills facing the USA, especially in response to the particular post from the GAO. If one was more guilty than the other on one topic (such as the prescription drug plan) the other party is more guilty on something else.>
fwiw, i'm not american, but probably would be considered more conservative (i.e. republican) in my views/support than liberal/democrat.
that said, two minor points in response - it was Walker of the impartial GAO (not me) that stated the Medicare prescription Drug Act (clearly the work of republicans) was the most irresponsible bill in decades costing $8 Trillion.
second, Walker seems to hold out hope that it will be political will (whether due to crisis or preferrably someone who actually is able to demonstrate real leadership before it becomes a crisis) that gets the US out of the mess, which i found rather ironic, given that in general, I agree with your observation that there is more than enough blame to go around with politicians of both parties for the current ills facing the US.
another more on topic aspect about this to consider is if this bill helped put $8 trillion into the pockets of big pharma & biotech (and presumably was/is reflected in their stock valuations) what will happen to those companies & their associated market valuations if/when the necessary changes to US healthcare are made (especially in the context of an FDA that seems ultra conservative)?
i'm not trying to provoke any endless political debate, but would be interested in hearing considered comments about what the fallout might be for big pharma & biotechs if healthcare undergoes a major reform that potentially could undo or significantly alter the effects of the maligned Medicare prescription drug act.
<Q. As I understand it, you regard the prescription-drug benefit as grossly irresponsible.
A. The most fiscally irresponsible act in decades.
Q. Are there other measures under consideration now that you would regard as equally irresponsible?
A.There are always some out there, but there are very few that come with $8 trillion price tags, which the Medicare prescription-drug bill did.>
so who was ultimately behind getting that piece of legislation passed, you ask? not to get too political, here, but just in case you were wondering...
"Democratic leaders call medicare drug legislation the product of a "corrupt legislative process," seek investigation into role of scandal-tainted lobbying group.
Washington, D.C. - In a (Jan. 25, 2006) letter to Speaker Hastert, Democratic Leader Pelosi, Democratic Whip Hoyer, and Ranking Member Waxman ask for a congressional investigation into the role played by the Alexander Strategy Group, a lobbying firm closely linked to Tom DeLay and Jack Abramoff, in the passage of the Medicare Prescription Drug Act and the drafting of the budget reconciliation bill currently before the Congress."
http://www.truthout.org/cgi-bin/artman/exec/view.cgi/48/17232
One of Alexander Strategy Group's biggest clients was Pharmaceutical Research and Manufacturers of America.
they represent the who's who of pharmaceutical research & biotech companies - check out their member companies...
http://www.phrma.org/about_phrma/member_company_list/members/
Lobby Giant Is Scandal Casualty
Abramoff, DeLay Publicity Blamed As Firm Closes
By Jeffrey H. Birnbaum and James V. Grimaldi
Washington Post Staff Writers
Tuesday, January 10, 2006; Page A01
One of Washington's top lobbying operations will shut down at the end of the month because of its ties to disgraced lobbyist Jack Abramoff and former House majority leader Tom DeLay.
Alexander Strategy Group, which had thrived since its founding in 1998 thanks largely to its close connections to DeLay (R-Tex.), will cease to operate except for a relatively small business-development division, Edwin A. Buckham, the former top DeLay aide who owns the company, said yesterday.
http://www.washingtonpost.com/wp-dyn/content/article/2006/01/09/AR2006010901996.html
ASG was founded by Ed Buckham, the former chief of staff to Texas GOP Congressman and House Majority Whip Tom DeLay, and Tony Rudy, a lobbyist for pharmaceutical companies and also a former top aide to DeLay.
Enron was ASG's biggest client; they received at least $411,000 from Enron between 1999 and 2001
The North Carolina-based private military contractor Blackwater USA hired ASG for crisis management, public and media relations as Blackwater - and private military contractors in general - came under increased public scrutiny following the public killing and mutilation of four employees in Fallujah, Iraq on March 31, 2004.
http://www.sourcewatch.org/index.php?title=Alexander_Strategy_Group
Insider Trading
While a DeLay staffer, Rudy traded hundreds of thousands of shares of stocks from his work computer in 1999 and 2000. From House disclosure forms it is impossible to determine whether Rudy profited or if he used insider knowledge. It is not illegal for Congressional staffers to trade upon insider legislative knowledge, although Louise Slaughter has introduced a bill banning the practice.
2000 Florida Recount
"Four of Abramoff's colleagues — all of whom have left Greenberg [Traurig] in the wake of investigations surrounding Abramoff’s activities — were foot soldiers in the Florida recount. Two of them bragged of their recount work on their official online Greenberg biographies, which have since been removed," John Byrne reported in the May 5, 2005, Raw Story.[9]
Also on the ground was former DeLay deputy chief of staff Tony Rudy"
http://en.wikipedia.org/wiki/Tony_Rudy#_note-3
and supposedly it is politicians who are to be entrusted to fix the problems their own kind helped create and benefited from???
sorry to sound so cynical, but it's hard not to be, imo.
<I almost took a stab at it at 428 the first time. Didn't. this one is such a freaking freight train I got run over once with 10,000 shares and dumped at the low.>
like i suggested in Msg 663, the 3 yr daily chart showed $4.25 as support if $4.45 didn't hold and that happened to be the low today (though it looks like someone dumped 1,000 shares AH at $4.24 to "paint the tape").
obviously no guarantees that it won't go lower still (largely dependent on the overall market, imo) but a fair amount of risk in this stock was removed with UK approval, and the chart suggests to me that once this skirmish with the bears is resolved (over the next month or so) it is headed higher.
at these prices, this is the time to be buying, since odds are they not only won't last very long, but they also should provide a nice return in a relatively short period of time.
all imho.
<Not much of a technical analyst but ole Golden Leopard from I Village talks about looking for that "W" bottom as a signal that it's time to buy. Looking at our chart from Oct. 1 until today sure looks like the last leg of that "W" formation.>
$4.45 support held up pretty good today as expected even tho the bears tried to take it lower during the first couple of hours of trading but couldn't. the bulls then stepped in & took control moving it up nicely the rest of the day. while that mirrored today's dow & nasdaq daily chart, i expect jav's 3 month, 6 month & 1 year chart over the next 12 months will resemble today's jav daily chart, fwiw, though i anticipate the return over the next 12 months to be much higher than today's meager 5%
cheers
ps - the 3 year jav chart (which shows the uptrend all the way back to Nov 05 when jav was $.25) suggests further support at $4.25 (if the bears ever managed to penetrate $4.45 support)
i might consider putting in a couple of stinker bids at $4.45 and again at $4.27 just in case the bears are able to break the major support at $4.45 - if they do, chances are it won't stay down there very long, so it is always good to be prepared
i know some don't ascribe much credence to technical analysis, particularly for a development stage biotech, but my read of the charts suggest that the stock is approaching an inflection point in the not too distant future (perhaps coinciding with certain events that drive fundamentals) that may be decisive in the battle between the bulls & bears, at least over the intermediate term.
the uptrend begun roughly this time last year got ahead of itself with jav going up too far too fast - not that surprising for a development stage biotech. it has obviously since corrected, in fact it overcorrected in mid august, thanks in part to the subprime credit crunch.
what is interesting is that just before that significant uptrend (from a low of $2.66 in oct/06 and hitting $7.60 in march - almost a 3 bagger), the stock sold off about 30% from mid august to the october low).
will history repeat? well, imo the odds aren't bad, especially considering they now have UK marketing approval for dyloject in the bag.
the chart tells me that the fight between the bulls & bears is heading for a potentially decisive battle in the near future - volume has not surprisingly picked up since UK approval, and while the price hasn't gone in the expected direction, there is little risk, imo that the stock will close below $4.45-$4.50 which is an area of solid support based on the trend line from the oct/06 low thru the aug/07 lows and the line of support line extending from the Jan/06 high thru the Feb/07 lows and Oct/07 lows.
on the bearish side, the downtrend line starting from the may/07 high thru the early June high and extending to the Oct/07 pre-approval high is headed for collision with the aforementioned uptrend line over the next month or so - and i suspect that this will prove to be a decisive "battle" for the near & intermediate term. I expect the bulls will prevail and jav to break out to the upside, perhaps sharply thanks to the almost 3M exposed shorts, where the previous highs in the mid $7 range are tested & eventually taken out.
of course, any significant market moving news could (& probably would) materially change the above scenario, however, barring that, i think the odds for the start of a decent 50 to 75% move to the upside over the next 6 to 8 weeks are pretty darn good, imo.
the current price is very attractive on a risk/reward basis, imo -
is it any wonder why there has been an influx to a formerly sleepy anonymous stock message board of a company that has just received long awaited drug approval - filling it with a lot of negative posts or just clutter? couldn't possibly be shorts seeing the same writing on the wall & looking to minimize the damage or even longs looking to talk the stock down & pick up some more cheapies?
technicals tell me the answer is quite plausibly yes.
<Resverlogix---Almost unbelievably, like SBS , also based in Calgary, and doing promising very early development with ApoA1.>
actually i bought in a while ago, primarily on the basis of them being able to attract some pretty credible people to their board, namely the likes of Dr. Roger Newton, one of the discoverers of Lipitor, to an otherwise hypish sounding management.
though they are only listed in canada, they are somehow on the SEC's Reg SHO list - McCaffrey, the CEO made a point of making this the first point addressed on their last cc in response to obvious shareholder concerns, which prompted a somewhat derisive sounding question from none other than Joe Edelman as to what that was all about...
i excluded them from my original list since they've been on a bit of a run as of late with a market cap over $350 Cdn and just entering Ph I
have heard of response & sembiosys from reading these boards, will have to check them out more closely...thanks
i was also going to mention yet another low-cap calgary company oncy as a possible value play, but it has taken them 8 long years to get a phase II trial going with their reovirus for various cancer indications. their management makes some of the rvx.to guys look like bill gates, but finally appear to have some reputable trials going on in the UK which is also the location of their sole institutional investor of note (Mellon-Newton) and a couple Ph I/IIs in the US, a systemic combo trial with radio/chemo on multiple late stage indications & one for glioblastoma iirc.
regards
How about some Canadian content to help reduce exposure to those sinking US greenbacks?
not sure if these are biotech values, but they do seem have very low market caps in relation to their potential value if they can translate their research into commercial success.
Amorfix Life Sciences AMF.to (market cap of about $50M Cdn)
from the company website
The company was formed in January 2004 to commercialize the discoveries of the epitope protection (EP) technologies at the University of Toronto discovered by Drs. Neil Cashman and Marty Lehto. These discoveries position the company to become the world authority on aggregated misfolded proteins (AMP) diseases (including Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (BSE) and the human form variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson's Disease (PD). The company will use this new knowledge to develop diagnostic kits, therapeutics and prophylactics for the AMP diseases.
Tekmira (formerly Inex) Pharmaceuticals tkm.to (market cap of about $33M Cdn)
has about 17M in working capital, relatively low burn and agreements with ALNY (granting ALNY worldwide exclusive license to liposomal delivery formulation technology and milestone payments for each product developed using tkm technology together with with tkm access to 3 InterfeRx™ license options from ALNY ) & HANA (licensed marquibo in ph 3 & two other ph I products), plus they have their own product candidates including INX-0167 which in pre-clinical studies demonstrated a strong immune response that translates into a dramatic enhancement in the anti-tumor activity of the monoclonal antibodies Rituxan® or Herceptin®.
Microbix Biosystems Inc.
mbx.to (market cap around $50M Cdn with some recent insider buying (tho small number of shares) by 4 different insiders) - has some interesting looking technology - eg. flu vaccine technology that apparently doubles production capacity using eggs, semen sexing technology for the AI market, and Urokinase for thromobylitc & oncology indications (though i am very much a layman in this regard, but not an egglayer
then there is the more familiar YM Biosciences ymi/ym.to ($75 Cdn Market cap which is approximately currently equal to cash on hand) with Nimotuzumab for Pediatric pontine glioma in Ph 3 trials conducted by Oncoscience AG & several other indications (also run by in-licensing partners) in ph 2) and recently nominating Dr. Philip Frost of imclone/erbitux fame to directorship.
and finally Medicure mph.to/mcu - $120M market cap, with an approved product on the market AGGRASTAT(R) and have pivotal ph 3 trial with 3,000 patient enrolment recently completed for MEND-CABG II for use as a cardioprotectant in patients undergoing CABG surgery. participant in financing has also purchased another 1.2M shares in the open market recently along with a couple of other insiders (who bought much smaller amounts).
anyone familiar with these companies have any thoughts on them? thanks in advance.
<I've pasted below the Reuters report on the recent news that appeared in my E*Trade account. Now, if you read this and didn't know better (a category under which the majority of retail falls) wouldn't you think this was bad news? Especially the headline.
Might be a brief selloff tomorrow morning before the real news sinks in, depending on how many people read only this.
Whoever writes biotech news at Reuters should be shot.>
easy there now rfj,...you're starting to sound like a former dndn conspiracist sharheolder like me now
Way <Way O/T: If Androxal facilitates a man being able to lick his own set, it will turn out to be bigger than Dr. Fleming's discovery of Peniscillin, er, penicillin.
(It will also put all divorce attorneys out of business, as no real man will ever marry again)>
somehow, even with that ability, i would hope women would take preeminence over "man's best friend"...unlike apparently the case with Buck the Bloodhound LMAO
i better stop now...just imagine though what Leno or Letterman could do with this story..the material would truly be endless.
absolutely hysterical.
OT <I wonder if Buck the Bloodhound also had a QoL improvement ?>
it gets better...
neuticles was "born" when the dog's owner couldn't take the look on his dog's face when it tried to lick its own balls & they weren't there...
you say this story sounds so bizarre, someone has to right a book on it...well they did!! read on LOL
Going Going NUTS! Excerpts
Page 23
Only another pet owner can relate to the anxiety associated with “castration"- a sterile and cold word for "neutering" or, better still-"altering".
For some the anxiety level is minimal-for others its' traumatic. For Buck and I- it was traumatic.
I had never had a pet neutered and did not realize the testicles are permanently removed in the process. Neutering is hideous enough- but to take away the testicles was too much. They were part of his identity-his personality. Buck would no longer be Buck!
Yet, if Buck wasn't neutered- he would take off again and the next time may not be found.
There were no options according to my lifelong veterinarian 'Doc Holder'.
Chemical castration is only temporary and cannot be used on a long-term basis. A Vasectomy on pets is useless as the pet still retains all 'mating' desires -and only 'shoots blanks'.
The appointment for surgery was scheduled.
It was a cold January morning. Buck knew something was going on as he hesitated to get in the car. I kept reminding myself of the benefits of neutering on the 22 mile drive to the vet’s office.
'Buck would be calmer, he wouldn't pick up the scent and be gone for days, the risk of testicular cancer is eliminated, he will be 'happier' in the long-term....'
Yet- the feeling of high anxiety kept returning -reminding me Buck would never be able to father puppies and would become female in appearance. It all seemed so unnatural.
We pulled up to the hospital but Buck refused to get out of the car. He sat in the back seat- firmly planted. He knew he was at the vets office and he hated going there.
The staff noticed my struggle to get him out of the car from inside the office and came out to see what was going on.
Lori, a vet technician, petted Buck in the back seat and after several soothing words followed her inside leaving me with two hours to wait while Buck met his fate.
"Buck will be just fine," Doc Holder said, knowing my concern over the situation.
Still searching for an option I asked Doc Holder a question. "Does someone make an implant so Buck could look the same? A testicular implant?"
Doc Holder was as surprised at me asking as I was of thinking of it. It seemed like a very logical question though.
"Gregg," Doc Holder laughed, "I've been a vet for over 45 years and no one has ever asked for such a thing."
Feeling like a neurotic pet owner I left the clinic to go visit Mom and Dad for the wait. Several hours later I returned to the hospital to pick Buck up.
"Buck did just fine," Doc Holder said. "He's ready to go home now but is still a little groggy."
Buck was a lot more cooperative leaving the hospital as he was going in. And, despite his ordeal, quickly but cautiously climbed into the back seat of the car to go back home.
Buck loved his ten acres and his home. Whenever he didn't feel well he would lie in the formal dining room by the bay window and sleep. That day was no exception.
Several hours later he awoke and had the sparkle in his eyes and his charismatic expressions back.
"Buckie- are you waking up?" I asked. He acknowledged my question by extending his paw- he wanted to shake. I shook his hand and rubbed his ears which he loved dearly.
"Buck- it's all over baby." He stretched with all his might -still waking up from his nap.
I still hadn't looked at the surgical area on Buck. I was blocking out the fact that a major change had been made- that if what was missing was ignored that somehow it wouldn't matter.
Buck then started to perform a task which he had performed since he was a puppy- cleaning himself.
He looked down at his "private area" to begin the process which was disgusting- mainly because of the noises he made doing it- a slurping noise that was gross and embarrassing especially when he did it while other people were around.
Buck looked up at me with a puzzled expression- his Bloodhound look of worry and concern.
He looked back down again -and then back at me a second time with an expression of "where did they go- what has happened to me?." He didn't clean himself- only had that look of bewilderment. Buck knew they were gone and for over a week seemed sluggish and depressed.
I took Buck back to the hospital to have his stitches removed. Doc Holder said Buck was recuperating just fine.
Then the conversation began. "Doc", I said, " I’ve been giving a lot of thought to Buck and our ordeal with neutering. What do you really think of testicular implants for the neuter-hesitant pet owner's pet?"
Doc Holder didn't laugh this time.
"Gregg, I’ve been giving it thought as well and you know- I think it's a very, very good idea," he said. "The more you think about it-the more sense it makes."
Doc Holder told me exactly what I needed to hear. And, at that moment the creation of Neuticles- testicular implants for dogs began.
ORDER GOING GOING NUTS!
http://www.goinggoingnuts.com/
i wonder who has the movie rights? LMAO
<The 5 Independent Research providers (unfortunately not listed) have a consensus of 3.8. 2 holds, 2 sells and 1 strong sell.
Who are these people? where can one find the list of independent analysts covering Repros.>
yahoo lists these 5 OTHER ANALYSTS
Abrahams, Brian of CIBC World Markets
Holterhoff, Chris of Thinkequity Partners
Kaplan, Matthew of Punk, Ziegel & Co.
Martin, David of Dundee Securities Corporation
Pathiparampil, Bino of Discovery Research-Thom Weisel
http://finance.yahoo.com/q/sa?s=RPRX
but Kaplan has a buy rating on them, so he at least isn't one of the 5 you are referring to
here is his report from a year ago, fwiw - he had a $25 target before the financing dilution when the price was $7.90
http://www.pzk.com/uploadedfiles/rprx090606.pdf
are you trying to suggest that if Provenge would have received FDA approval, the sub-prime crisis wouldn't have occurred?????
sorry, but that is too conspiracist for even me. while i do think the FDA's Provenge decision was influenced by big money, and that there is widespread corruption in the financial markets (SEC & Reg SHO, hedge funds, etc.) i don't think there is any correlation between these two events.
biotechs in general probably would have rallied on Provenge approval and a hedge fund or two short DNDN might have blown up (if they weren't allowed to continue short selling counterfeit shares) but there is absolutely no way imo that the CR for Provenge contributed to or was caused by the unravelling of predatory lending of unsustainable mortgages.
no doubt there are some large predators out there who deliberately set things up for a fall so they can swoop in afterwards and gain control at a huge discount, but imo they aren't anywhere near big enough (yet) to control or even influence macroeconomic factors, though i do think if they were big enough, they wouldn't think twice.
>>Way OT-Real estate billionaire Leona Helmsley left $12 million in her will for her dog.
wonder if michael vick (or more likely his attorney/agent responsible for "rehabilitating" his career) is taking any notes?
sorry couldn't resist.
Thanks Wall. I hope your last sentence turns out to be incorrect, but certainly don't discount it.
More OT - It didn't hit me until i read your post, but in terms of liquidity, who possibly has more of it than the Chinese, increasingly selling their wares to us North Americans & taking our greenbacks in return?
if i was the head of a government of the largest population on the planet, that was emerging as a fast-growing competitor to the free market economies of the west for the same important yet scarce resources (oil, metals & other commodities), committed to central planning & control, and denied from using some of that surplus cash to acquire strategic assets such as Unocal, but was permitted to put some money ($3B) into influential private equity hedge funds like Blackstone, i might look at leveraging my power (i.e. increasing liquidity) and attacking the softest part of the underbelly (eg. subprime mortgages) with the purpose of creating a liquidity crisis that threatens to if not actually lowers prices of certain if not all asset classes, so that i can later swoop in and use some of my huge liquidity and acquire such assets at a considerable discount...
sorry if this sounds ultra-conspiratorialist, but what safeguards are there to prevent someone large enough (like a chinese government with huge foreign reserves of $US - maybe up to a trillion now?) from precipitating an actual (or contrived) crisis to secure their longer term objectives?
i think their version of the golden rule is whoever has the gold makes the rules...
sorry for the OT, rfj, have you started that new thread yet?
<That 1 in a million chance that you mentioned is off. I think there were 7 or 8 zeros in the p value, so it should be more like a 1 in 100 million or 1 in a billion that those Avastin Phase 3 results were due to chance. Amazing, isn't it...>
i try to follow biotechs (obviously nowhere near the extent & depth some of you guys do), but when i read stuff like this it boggles my mind as to how this type of apparently transparent impropriety can be allowed to go on.
i no longer hold any financial interest in DNDN and don't actively follow its MB at ivillage only Ihub's DNDN message board with any regularity, but was wondering wall, if you have any thoughts about the lawsuit being brought against the FDA by some DNDN shareholders/prostate cancer patients & advocates (i think it is caretolive.org), specifically its chances of exposing dirt on Scher, the Cancer Letter and who at the FDA was responsible for leaking the letters to TCL and if successful in uncovering any dirt, whether you think there would be enough newsworthiness and/or egregiousness that it might make a difference in a) causing anyone at the FDA involved to be removed from their position and/or b) having the FDA have a new look at the Provenge decision?
fwiw, i hope for the sake of the advancement of science and a healthy biotech sector, this lawsuit succeeds in its goals.
thanks in advance for any thoughts you might have.
<You've got to believe that some of the hedge fund crisis will spill over into small-cap biotech. That coupled with tax-loss selling could make for a brutal September/October, unless the FED comes to the rescue.>
at what point does the fed printing easy money to bail out irresponsible big money hedge fund failures to avoid a liquidity crisis that could precipitate a deflationary downward spiral and a complete market meltdown, itself spark runaway inflation by devaluing the dollar and ultimately result in the same end...a financial market meltdown?
it looks to me like the underpinnings of the entire financial system (pension funds, insurance companies, individual investors, etc.) are starting to come undone like rivets popping on the titanic...
gold bullion looking pretty good these days...and i'm not sure that even when there is blood in the streets it will be time to buy stocks as it might just be the beginning...
in fact, i suspect the potential social upheaval that a collapse of the financial system would cause would be unlike anything seen since the great depression (and perhaps much worse).
this looks like serious, scary stuff to me.
<make no mistake this was planned.>
i tend to agree. the following story, based on the byline, was released 3 minutes after DNDN released the news (and this morning it appears on yahoo's news headlines).
Breast cancer vaccine looks safe, study shows
By Maggie Fox, Health and Science Editor Fri Aug 17, 6:03 PM ET
WASHINGTON (Reuters)
A vaccine designed to treat breast cancer appeared to be safe in women with advanced disease and showed signs of actually slowing down tumors, U.S. researchers reported on Friday.
Dendreon Corporation, maker of the Provenge prostate cancer vaccine, calls the new vaccine Neuvenge. It targets a type of breast cancer called her2/neu-positive breast cancer, which affects between 20 percent and 30 percent of breast cancer patients.
Like Provenge, Neuvenge is made using immune cells from the cancer patient, so it is a tailor-made vaccine.
Dr. John Park of the University of California, San Francisco and colleagues tested it in 18 women with advanced her2/neu-positive breast cancer, whose cancer had spread despite treatment.
Writing in the Journal of Clinical Oncology, the researchers said the vaccine did not cause any serious side effects and appeared to help at least one patient.
"We saw a partial response, meaning a reduction in the size of tumor area in one patient that was certainly attributable to the treatment," Park said in a telephone interview.
In three other women, their cancer appeared to stabilize for as long as a year, something that could have been due to treatment, Park said.
Park said the effects justify moving from the Phase 1 safety trial to a Phase 2 trial, which would be designed to show the treatment actually helps patients. But that may not happen for a while, he said.
FULL PLATE
"The sponsor of this vaccine technology, Dendreon, is also associated with Provenge," Park said.
"We on the breast cancer side are trying to encourage them to develop Neuvenge with the same vigor that they have tried to apply to Provenge, but it is not a company that has unlimited resources."
In January, the U.S. Food and Drug Administration accepted Dendreon's marketing application for Provenge on a "fast-track" basis, and in March an advisory panel said Provenge appeared reasonably safe. But the FDA has asked Dendreon to show the vaccine helps prostate cancer patients actually live longer.
Dr. Dave Urdal, chief scientific officer at Seattle-based Dendreon, said that data would not be available any sooner than next year, and perhaps not until 2010.
"The company currently is focused on its lead product, Provenge, so moving forward with the Neuvenge product is something that we haven't given guidance on," Urdal said in a telephone interview.
The delay in approval of Provenge has angered some patient advocacy groups.
Urdal said both Provenge and Neuvenge make use of immune system cells called CD4 helper T-cells.
"This validates the approach. So there is more than one target and more than one cancer that potentially will benefit from this form of therapy," he said. Other companies are also working on cancer vaccines.
The her2/neu protein is over-expressed, meaning it is over-active, in several tumors including breast, colorectal and ovarian cancer.
The vaccine is a therapeutic vaccine, meaning it stimulates an immune response to existing disease. The patient's T-cells are removed, "trained" to recognize the her2/neu protein, and then re-infused into the patient.
http://news.yahoo.com/s/nm/20070817/sc_nm/cancer_breast_neuvenge_dc
it looks to me like they are trying to draw attention to Provenge (which acts like Neuvenge) with the women's lobby groups to help organize & support the efforts of the PC groups in lobbying the FDA & the govt, more than looking for any temporary pop in the share price until investors realize neuvenge for breast cancer isn't going anywhere anytime soon.
that isn't necessarily a bad strategy, imo, fwiw.
<Dendreon should initiate a combo trial of Provenge+taxotere vs taxotere (standard of care)ASAP.
This trial would be the next logical step anyway, regardless if 9902b succeeds or fails. And could be used as a backup for approval.>
good point.
i know there are potentially significant financial considerations, but that said, i don't understand why DNDN hasn't at least tried to force a potential euro partner's (aka Sanofi's) hand by starting a provenge/tax combo trial and/or expanding 9902B clinical trial centers to europe to at least start the timeline for euro approval (assuming the euros won't just accept FDA approval as basis for euro approval).
its been pointed out by others before many times, but why not just partner now for euro & get that ball to commercialization rolling, rather than wasting 2 or 3 years waiting for US results???
it makes little sense not to, imo, as a former DNDN long, fwiw.
Re: Resverlogix Jul 31/07 CC - a couple of interesting notes on this (especially after having gone thru DNDN Reg SHO & Joe Edelman)
CEO McCaffrey began the call by commenting on their recent $25M convertible debenture notes financing & its structure - namely the part about if any of the debenture notes were converted at a time when the stock traded below the $17.50 Cdn threshold (approximately the price at the time the Jun financing was announced) then resverlogix would pay interest on the notes thru to maturity.
the stock had hit a high of $29.50 in February after a similar $15M debenture financing in January and then dropped precipitously to a low of $10.50 in early April before recovering. It hit $22 in early June just before the latest financing announcement.
the price subsequently dropped below the $17.50 threshold shortly afterwards and continued dropping to a recent low of $7.01, which prompted today's <a href="http://www.resverlogix.com/upload/latest_news/45/01/2007-08-13_interest_rate-conversion_press_releas.... news release</a> announcing that the interest rates on the notes have increased to 12 & 13% (from 8%) due to the stock trading below the Jan & Jun conversion prices and that certain debenture holders had converted some debentures while the stock traded below the conversion prices.
mccaffrey stated he fully believes that someone is perpetrating illegal stock trading and putting downward pressure on the stock but refrained from accusing any of the partakers of the recent financing.
interestingly, that prompted the first cc question from perceptive advisors' joe edelman about what mcaffrey's comment about "illegal manipulation" was about. mcaffrey's response was to reiterate that the company has contacted Cdn regulatory authorities (who are largely ineffectual when it comes to enforcement when compared to the SEC, imo) and let them handle it. earlier, McCaffrey suggested investors contact their relevant regulators, and even suggested to US listeners to avoid buying stock on the "pink sheets" & purchase them on the TSE as they aren't listed in the US & accordingly aren't subject to any regulatory controls in his opinion. he also indicated he would pursue this illegal shorting issue even if & when the company was sold successfully.
another note of interest - rvx appears on Reg SHO (having apparently first appeared there on Jan 16, 2007, 11 days after closing their original $15M debenture financing)
ftp://ftp.nasdaqtrader.com/symboldirectory/regsho/nasdaqth20070116.txt
as for the rest of the cc, it certainly appears mccaffrey is strongly suggesting that the company (i.e. technology platform) is for sale to big pharma and they are actively in negotiations with interested parties (hinting large pharma) - and if the phase I trials suggest any hint of efficacy the asking price will go up much higher...how much of that is hype and how much is based on a sincere belief & confidence in what they have and more importantly on their ability to execute & deliver is open to debate.
as for the current share price technicals, (closed at $8.28 Cdn today, down $.62), recent RSI levels (below 30 since late July) suggest the stock may be bottoming, fwiw.
<Resverlogix held a CC yesterday (Wednesday); I hadn’t planned to listen but now maybe I will.>
actually, i think today is Wednesday, but at this time of nite, i'm not really sure. lol
looking forward to hearing your comments about the cc (which apparently was held yesterday Jul 31 at noon (not today Aug 1 as my earlier post stated), if you do get a chance to listen to it.
regards stuck.
re: resverlogix (rvx.to), they do seem to have pumped this news just a bit
Dr. Roger Newton, Co-Discoverer of Lipitor(R), Joins Resverlogix Board of Directors
Monday May 14, 9:00 am ET
CALGARY, ALBERTA--(MARKET WIRE)--May 14, 2007 -- Resverlogix Corp. ("Resverlogix") (Toronto:RVX.TO - News) is pleased to announce today that the Board of Directors has appointed Roger Newton, PhD, to the Board effective July 10, 2007.
"I am very pleased to be joining the Board of Directors of Resverlogix. It is a very exciting time for the NexVas(TM) Plaque Regression technology", stated Dr. Newton. "We know that raising ApoA-l and functional HDL can regress atherosclerosis and this technology has the potential to be first in a new class of drugs for the treatment of cardiovascular disease due to atherosclerosis."
http://biz.yahoo.com/iw/070514/0252338.html
and again recently here
Resverlogix Corp.: Dr. Roger Newton, Co-Discoverer of Lipitor(R), Commences his Board of Directors Position
Thursday July 12, 9:30 am ET
CALGARY, ALBERTA--(MARKET WIRE)--Jul 12, 2007 -- Resverlogix Corp. ("Resverlogix") (Toronto:RVX.TO - News) is pleased to announce today that Dr. Roger Newton has joined the Board of Directors effective immediately.
"This is a fascinating time to be joining Resverlogix's Board of Directors as momentum is gaining for the NexVas(TM) Plaque Regression technology," stated Dr. Newton. "The excitement for me comes from knowing that by raising ApoA-l and functional HDL we can regress atherosclerosis. Thus the opportunity to be first in an entire new class of drugs for the treatment of cardiovascular disease due to atherosclerosis is very appealing."
http://biz.yahoo.com/iw/070712/0277269.html
but it certainly sounds as if there is something to their "NexVas(TM) Plaque Regression technology", having been able to attract some apparently noteworthy & reputable collaborators.
the pumping seems to have had a short-lived effect on the stock price...having gone from $10.50 on april 3 to $22.50 on june 1, then back down, hitting below $10 yesterday, before closing at $10.15 Cdn
the question - does it represent a value (with about 25M shares o/s) at current price? TA suggests the possibility of a decent bounce from here, with support having held, (perhaps a good longer term entry point) while the science seems to suggest this could be more than just a short term pump (and in that regard, they have another conference call scheduled for later today at noon MDT http://biz.yahoo.com/iw/070731/0284458.html )
comments anyone?
<When Dewophile posted this, JAV became dead for at least a few weeks....>
actually, i think it coincided more with rfj1862's posting this on Jun 18th
"JAV
I find it very irritating that I have a 12000-share limit order in for JAV and it's not getting filled while others are getting filled at 5.80 to 5.84."
http://investorshub.advfn.com/boards/read_msg.asp?message_id=20539207
rjf1862, did you manage to pick up any at $5.85?
fwiw, that is a terrific ad - focuses on the facts without resorting to emotionally charged accusations, conspiracy theories, etc. and asks the right questions for which reasonable answers/explanations aren't available and haven't been forthcoming.
i'm no longer a DNDN shareholder, but for the sake of AIPC patients and DNDN shareholders, i hope the ad serves its intended purpose, though i fear the same (big money) interests that imo helped kill Provenge approval will unfortunately succeed in killing any potential FDA reversal.